204 related articles for article (PubMed ID: 34227708)
1. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.
Kim SH; Cho KB; Chun HJ; Lee SW; Kwon JG; Lee DH; Kim SG; Jung HY; Kim JW; Lee JS; Park H; Choi SC; Jee SR; Kim HS; Ko KH; Park SJ; Lee YC; Park SH; Kim AR; Kim EJ; Park HW; Kim BT; Song GS
Aliment Pharmacol Ther; 2021 Aug; 54(4):402-411. PubMed ID: 34227708
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
Cho YK; Choi MG; Choi SC; Lee KM; Kim TO; Park SH; Moon JS; Lim YJ; Kang DH; Cheon GJ; Baik GH; Kim KO; Cho KB; Jang JS; Park JJ; Son BK; Jung HK; Kim BW; Kim SK; Lee ST; Cha JM; Kim AR; Kim EJ; Park HW; Song GS
Aliment Pharmacol Ther; 2020 Sep; 52(5):789-797. PubMed ID: 32701188
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study.
Kinoshita Y; Sakurai Y; Takabayashi N; Kudou K; Araki T; Miyagi T; Iwakiri K; Ashida K
Clin Transl Gastroenterol; 2019 Nov; 10(11):e00101. PubMed ID: 31770139
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of Amla (Phyllanthus emblica L.) in non-erosive reflux disease: a double-blind, randomized, placebo-controlled clinical trial.
Karkon Varnosfaderani S; Hashem-Dabaghian F; Amin G; Bozorgi M; Heydarirad G; Nazem E; Nasiri Toosi M; Mosavat SH
J Integr Med; 2018 Mar; 16(2):126-131. PubMed ID: 29526236
[TBL] [Abstract][Full Text] [Related]
6. Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial.
Kim JS; Seo SI; Kang SH; Lee SK; Kim AR; Park HW; Kim BT; Song GS
J Neurogastroenterol Motil; 2023 Jan; 29(1):58-64. PubMed ID: 36581325
[TBL] [Abstract][Full Text] [Related]
7. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
8. Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J; Mermelstein AC; Chait MM
Drugs Today (Barc); 2020 Nov; 56(11):715-721. PubMed ID: 33332479
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease.
Fass R; Vaezi M; Sharma P; Yadlapati R; Hunt B; Harris T; Smith N; Leifke E; Armstrong D
Aliment Pharmacol Ther; 2023 Nov; 58(10):1016-1027. PubMed ID: 37750406
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study.
Jeon HK; Kim GH; Cheon YI; Shin SC; Lee BJ
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834761
[TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Kinoshita Y; Ashida K; Hongo M;
Aliment Pharmacol Ther; 2011 Jan; 33(2):213-24. PubMed ID: 21083596
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.
Kinoshita Y; Sakurai Y; Shiino M; Kudou K; Nishimura A; Miyagi T; Iwakiri K; Umegaki E; Ashida K
Curr Ther Res Clin Exp; 2016; 81-82():1-7. PubMed ID: 28119763
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects.
Han S; Choi HY; Kim YH; Nam JY; Kim B; Song GS; Lim HS; Bae KS
Aliment Pharmacol Ther; 2019 Oct; 50(7):751-759. PubMed ID: 31437865
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.
Sunwoo J; Ji SC; Oh J; Ban MS; Nam JY; Kim B; Song GS; Yu KS; Jang IJ; Lee S
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1640-1647. PubMed ID: 33131095
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
[TBL] [Abstract][Full Text] [Related]
17. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY
J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
Chiu CT; Hsu CM; Wang CC; Chang JJ; Sung CM; Lin CJ; Chen LW; Su MY; Chen TH
Aliment Pharmacol Ther; 2013 Nov; 38(9):1054-64. PubMed ID: 24024757
[TBL] [Abstract][Full Text] [Related]
19. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease.
Park SH; Lee KN; Lee OY; Choi MG; Kim JH; Sung IK; Jang JY; Park KS; Chun HJ; Kim EY; Lee JK; Jang JS; Kim GH; Hong SJ; Lee YC; Choi SC; Kim HS; Kim TO; Baik GH; Jeon YC
Gut Liver; 2023 Mar; 17(2):226-233. PubMed ID: 35730245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
